---
title: "Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300435099.md"
description: "Dianthus Therapeutics (Nasdaq: DNTH) announced plans to present data on claseprubart at the AANEM Annual Meeting in Orlando, scheduled for September 29–October 2, 2026. The company will feature one oral presentation and four poster presentations. As a clinical-stage biotech firm focused on severe autoimmune diseases, this event highlights their ongoing research and innovation efforts."
datetime: "2026-09-29T12:03:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300435099.md)
  - [en](https://longbridge.com/en/news/300435099.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300435099.md)
generator: "portal-rs"
---

# Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

On September 29, 2026, Dianthus Therapeutics, Inc., a clinical-stage biotechnology company based in New York and Waltham, Massachusetts, revealed its plans for showcasing claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in Orlando, Florida. The event, scheduled from September 29 to October 2, 2026, will feature one oral presentation and four poster presentations by Dianthus Therapeutics. As a company listed on Nasdaq under the symbol DNTH, Dianthus focuses on pioneering advanced treatments for severe autoimmune diseases. This development underscores their commitment to transforming disease management in this space and signifies a significant step forward in the realm of biotechnology research and innovation.

### Related Stocks

- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)

## Related News & Research

- [Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meeting](https://longbridge.com/en/news/300432141.md)
- [Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile](https://longbridge.com/en/news/299429976.md)
- [Microsoft Could Be SpaceX's Next Big AI Customer: Bernstein Sees AI Revenue Surging Nearly 500%](https://longbridge.com/en/news/300953883.md)
- [Tesla Stock Forecast: Q3 Delivery Beat Shifts Focus to Margins and AI](https://longbridge.com/en/news/300929376.md)
- [Stifel lifts year-end target for S&P 500 to 7,900](https://longbridge.com/en/news/300948178.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**